GNH USA

Europe — EMA

Myxina (Nimesulide)

GNH USA supplies Myxina (Nimesulide), an NSAID for pain relief, inflammation reduction and osteoarthritis. Request a quote for global supply to providers.

Nimesulide

Request sourcing

1
Pack/s

What is Nimesulide?

Nimesulide, the active ingredient in Myxina, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as an oral tablet for oral use. It treats pain and inflammation in conditions such as osteoarthritis, dysmenorrhea and fever, and is approved in the European Union for short‑term management of mild to moderate pain and inflammatory disorders.

GNH USA supplies Myxina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with capabilities for regulatory compliance, quality assurance and reliable global logistics to providers.

What is Nimesulide used for?

Nimesulide is an NSAID that reduces inflammation and pain by inhibiting cyclooxygenase‑2. - Pain relief: provides analgesic effect for mild to moderate acute pain. - Inflammation reduction: decreases swelling and redness in inflammatory conditions. - Osteoarthritis: alleviates joint pain and improves mobility in osteoarthritic patients. - Dysmenorrhea: reduces menstrual cramps and associated discomfort. - Fever: helps lower elevated body temperature during febrile episodes.

What are the side effects of Nimesulide?

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia, or abdominal pain. - Headache: mild to moderate intensity. - Dizziness: transient sensation of light‑headedness. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Hepatic injury: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal impairment: reduced kidney function or acute renal failure. - Cardiovascular events: increased risk of thrombotic events. - Blood dyscrasias: anemia, leukopenia, or thrombocytopenia. - Anaphylaxis: rare but potentially life‑threatening allergic reaction.

What precautions apply to Nimesulide?

Before initiating therapy, consider the following precautions: - Assess liver function: check baseline hepatic enzymes before starting treatment. - Avoid in patients with known hypersensitivity to nimesulide or other NSAIDs. - Use the lowest effective dose for the shortest duration to limit gastrointestinal risk. - Caution in patients with renal impairment or heart failure. - Avoid concomitant use with other COX‑2 inhibitors or high‑dose aspirin. - Store at ambient temperature below 25 °C: keep in the original pack, protect from moisture.

What does Nimesulide interact with?

Nimesulide may interact with several medicines; monitoring is advised. Major Interactions (Avoid): - Concurrent use with other NSAIDs or COX‑2 inhibitors: increased risk of gastrointestinal bleeding. - Combination with anticoagulants (e.g., warfarin, heparin): heightened bleeding risk. - Co‑administration with hepatotoxic drugs (e.g., isoniazid, methotrexate): potential liver injury.

Moderate Interactions (Monitor Closely): - Use with antihypertensives (ACE inhibitors, diuretics): may reduce renal perfusion. - Combination with lithium: possible increase in lithium serum levels. - Use with corticosteroids: additive risk of gastrointestinal complications.

Frequently asked questions

What is Myxina used for?+
Myxina contains nimesulide, an NSAID indicated for short‑term relief of mild to moderate pain and inflammation associated with conditions such as osteoarthritis, dysmenorrhea, and fever. It works by reducing prostaglandin production, helping to alleviate discomfort and swelling.
How does nimesulide work?+
Nimesulide selectively inhibits the cyclooxygenase‑2 (COX‑2) enzyme, which converts arachidonic acid into prostaglandins that mediate pain, fever and inflammation. By blocking COX‑2, the drug lowers prostaglandin levels at the site of injury, providing analgesic and anti‑inflammatory effects while sparing COX‑1 activity.
What is the usual dose of Myxina?+
The appropriate dose of Myxina is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, and response to therapy. The prescriber will select the strength and dosing schedule that best balances efficacy with safety, following local regulatory guidelines.
Is Myxina safe during pregnancy or breastfeeding?+
Safety of nimesulide in pregnancy and lactation has not been established, and the drug is generally avoided in these populations unless the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatments with their healthcare provider.
How do I order Myxina from GNH USA?+
To place an order, submit an enquiry on the Myxina product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.
How does Myxina compare with other NSAIDs?+
Compared with non‑selective NSAIDs such as ibuprofen, nimesulide offers relatively greater COX‑2 selectivity, which may reduce gastrointestinal side effects in some patients. However, it carries its own risk profile, including potential hepatic effects, and should be chosen based on individual patient factors and physician judgment.
What are the storage requirements for Myxina?+
Myxina should be stored at ambient temperature below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.
How is Myxina administered?+
Myxina is taken orally, usually with a full glass of water. It may be taken with or without food, although taking it with meals can help lessen gastrointestinal discomfort. Patients should follow the dosing instructions provided by their prescriber.
What are the most serious risks associated with Myxina?+
The most serious adverse reactions include severe liver injury, life‑threatening skin reactions such as Stevens‑Johnson syndrome, and significant renal impairment. Patients should be monitored for signs of hepatic dysfunction, rash, or decreased urine output, and the drug should be discontinued immediately if such events occur.
Who should not use Myxina?+
Myxina is contraindicated in individuals with known hypersensitivity to nimesulide or other NSAIDs, those with active peptic ulcer disease, severe hepatic or renal impairment, and patients receiving other COX‑2 inhibitors. It should also be avoided in pregnant women unless absolutely necessary.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Nimesulide
Route
Oral Use
Manufacturer
Norma Hellas S.A.
Origin
EU

Related products

Actalide

Actalide

Nimesulide

Errekappa Euroterapici Spa
EU
Actalide

Actalide

Nimesulide

Errekappa Euroterapici Spa
EU
Algolider

Algolider

Nimesulide

Siar Pharma S.R.L.
EU
Aponil

Aponil

Nimesulide

Medochemie Ltd.
EU